ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.95802
-0.15%
Brent Oil
83.12
-0.01%
Bitcoin
64,092.96
0.15%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Myriad Genetics Inc (MYGN)

  7. Myriad Genetics Inc (MYGN) Noticias

MYGN Myriad Genetics Inc

19.43
0.21 (1.09%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Myriad Genetics Inc MYGN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.21 1.09% 19.43 16:58:41
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
19.85 19.40 20.09 19.47 19.22
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202415:05GLOBEMyriad Genetics to Release First Quarter 2024 Financial..
17/4/202407:00GLOBENearly Half of Americans Say They’ve Lost Time in Their..
16/4/202408:15GLOBENew Myriad Genetics Study Published in Prenatal Diagnosis..
09/4/202407:00GLOBEMyriad Genetics Research Shows Reduction in Hospitalizations..
21/3/202420:40GLOBEMyriad Genetics Announces Foundational Patent Granted for..
20/3/202415:05GLOBEMyriad Genetics Announces Patent Granted for SneakPeek® Snap..
04/3/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202407:31EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202415:05EDGAR2Form 8-K - Current report
27/2/202415:05GLOBEMyriad Genetics Reports Strong Fourth Quarter and Full-Year..
27/2/202408:15GLOBEMyriad Genetics and National Cancer Center Hospital East in..
26/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:05GLOBEMyriad Genetics to Release Fourth Quarter and Full Year 2023..
15/2/202415:05GLOBEMyriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as..
14/2/202415:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202407:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202409:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202408:25GLOBEMyriad Genetics Completes Acquisition of Precise Tumor,..
31/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202416:00GLOBEMyriad Genetics Names George Daneker Jr., MD, as President..
29/1/202415:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202415:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/1/202415:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202413:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202417:10GLOBEMyriad Genetics to Acquire Precise Tumor, Precise Liquid and..
16/1/202408:00EDGAR2Form 8-K - Current report
09/1/202415:05GLOBEMyriad Genetics Applauds New Germline Testing Guideline for..
03/1/202415:05GLOBEMyriad Genetics to Present at 42nd Annual J.P. Morgan..
02/1/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202307:30EDGAR2Form 8-K - Current report
21/12/202307:30GLOBEMyriad Genetics Chief Financial Officer Bryan Riggsbee..
20/12/202307:00GLOBEMyriad Genetics Establishes Comprehensive Pan-Cancer..
11/12/202317:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202317:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/12/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202315:05GLOBEMyriad Genetics Celebrates One Million SneakPeek® Results..
16/11/202315:05GLOBEMyriad Genetics and Personalis Partner to Market..
13/11/202315:31EDGAR2Form 8-K - Current report
13/11/202305:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/11/202306:00GLOBEMyriad Genetics to Participate in Stephens Annual Investment..
08/11/202320:20GLOBEMyriad Genetics Announces Pricing of Upsized Offering of..
08/11/202320:16EDGAR2Form 8-K - Current report
08/11/202315:10GLOBEMyriad Genetics Announces Proposed Offering of $100 Million..
08/11/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/11/202315:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
07/11/202307:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:05EDGAR2Form 8-K - Current report
06/11/202315:05GLOBEMyriad Genetics Reports Third Quarter 2023 Financial..
03/11/202316:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
MYGN
Myriad Genetics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados